Follow
Ahmed Nader
Ahmed Nader
GSK
Verified email at abbvie.com
Title
Cited by
Cited by
Year
Intravenous versus oral acetaminophen for pain: systematic review of current evidence to support clinical decision-making
F Jibril, S Sharaby, A Mohamed, KJ Wilby
The Canadian journal of hospital pharmacy 68 (3), 238, 2015
1852015
Identification of HLA-DRB1 association to adalimumab immunogenicity
M Liu, J Degner, JW Davis, KB Idler, A Nader, NM Mostafa, JF Waring
PLoS One 13 (4), e0195325, 2018
742018
Clinical pharmacology of elagolix: an oral gonadotropin-releasing hormone receptor antagonist for endometriosis
M Shebley, AR Polepally, A Nader, JW Ng, I Winzenborg, CE Klein, ...
Clinical pharmacokinetics 59 (3), 297-309, 2020
492020
Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration
RF Eyler, AM Vilay, AM Nader, M Heung, M Pleva, KM Sowinski, ...
Antimicrobial agents and chemotherapy 58 (3), 1320-1326, 2014
462014
Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis
NM Mostafa, AM Nader, P Noertersheuser, M Okun, WM Awni
Journal of the European Academy of Dermatology and Venereology 31 (3), 490-497, 2017
382017
Pharmacokinetics of upadacitinib in healthy subjects and subjects with rheumatoid arthritis, Crohn's disease, ulcerative colitis, or atopic dermatitis: population analyses of …
A Nader, S Stodtmann, A Friedel, MEF Mohamed, AA Othman
The Journal of Clinical Pharmacology 60 (4), 528-539, 2020
352020
Clinical and pharmacokinetic outcomes of peak–trough-based versus trough-based vancomycin therapeutic drug monitoring approaches: A pragmatic randomized controlled trial
FK Al-Sulaiti, AM Nader, MO Saad, A Shaukat, R Parakadavathu, ...
European Journal of Drug Metabolism and Pharmacokinetics 44, 639-652, 2019
352019
Suitability of digoxin as a P‐glycoprotein probe: implications of other transporters on sensitivity and specificity
AM Nader, DR Foster
The Journal of Clinical Pharmacology 54 (1), 3-13, 2014
352014
Population pharmacokinetics and immunogenicity of adalimumab in adult patients with moderate-to-severe hidradenitis suppurativa
A Nader, D Beck, P Noertersheuser, D Williams, N Mostafa
Clinical Pharmacokinetics 56, 1091-1102, 2017
342017
Population pharmacokinetics of intravenous methotrexate in patients with hematological malignancies: utilization of routine clinical monitoring parameters
A Nader, N Zahran, A Alshammaa, H Altaweel, N Kassem, KJ Wilby
European journal of drug metabolism and pharmacokinetics 42, 221-228, 2017
332017
Effect of Gastric Fluid Volume on the In Vitro Dissolution and In Vivo Absorption of BCS Class II Drugs: a Case Study with Nifedipine
AM Nader, SK Quinney, HM Fadda, DR Foster
The AAPS Journal, 1-8, 2016
322016
Population pharmacokinetics of elagolix in healthy women and women with endometriosis
I Winzenborg, A Nader, AR Polepally, M Liu, J Degner, CE Klein, ...
Clinical pharmacokinetics 57, 1295-1306, 2018
282018
A semi‐mechanistic metabolism model of CYP3A substrates in pregnancy: predicting changes in midazolam and nifedipine pharmacokinetics
SK Quinney, AN Mohamed, MF Hebert, DM Haas, S Clark, JG Umans, ...
CPT: pharmacometrics & systems pharmacology 1 (9), 1-9, 2012
252012
Exposure–response analyses of upadacitinib efficacy and safety in phase II and III studies to support benefit–risk assessment in rheumatoid arthritis
A Nader, MEF Mohamed, I Winzenborg, E Doelger, P Noertersheuser, ...
Clinical Pharmacology & Therapeutics 107 (4), 994-1003, 2020
232020
A genetic variant in the BCL2 gene associates with adalimumab response in hidradenitis suppurativa clinical trials and regulates expression of BCL2
M Liu, J Degner, RW Georgantas, A Nader, NM Mostafa, HD Teixeira, ...
Journal of Investigative Dermatology 140 (3), 574-582. e2, 2020
212020
Gentamicin pharmacokinetics and pharmacodynamics during short-daily hemodialysis
BS Decker, AN Mohamed, M Chambers, MA Kraus, SM Moe, ...
American journal of nephrology 36 (2), 144-150, 2012
162012
Long‐term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis
R Gniadecki, CL Leonardi, KB Gordon, Y Gu, Z Geng, A Nader, ...
Journal of the European Academy of Dermatology and Venereology 32 (8), 1297-1304, 2018
142018
Exposure‐safety analyses identify predictors of change in bone mineral density and support elagolix labeling for endometriosis‐associated pain
A Abbas Suleiman, A Nader, I Winzenborg, D Beck, AR Polepally, J Ng, ...
CPT: Pharmacometrics & Systems Pharmacology 9 (11), 639-648, 2020
122020
Drug–drug interaction studies of elagolix with oral and transdermal low-dose hormonal add-back therapy
A Nader, NM Mostafa, F Ali, M Shebley
Clinical pharmacokinetics 60, 133-143, 2021
102021
Intramuscular vs intravenous SARS-CoV-2 neutralizing antibody sotrovimab for treatment of COVID-19 (COMET-TAIL): a randomized noninferiority clinical trial
AE Shapiro, E Sarkis, J Acloque, A Free, Y Gonzalez-Rojas, R Hussain, ...
Open forum infectious diseases 10 (8), ofad354, 2023
8*2023
The system can't perform the operation now. Try again later.
Articles 1–20